Adenovirus lacking the 19-kDa and 55-kDa E1B genes exerts a marked cytotoxic effect in human malignant cells

Cancer Gene Therapy

Volumn 6, Issue 6, 1999, Pages 554-563

  Duque, Pilar Martín ^a   Alonso, Covadonga ^b   Sánchez Prieto, Ricardo ^a   Lleonart, Matilde ^a   Martínez, Carlos ^c   De Buitrago, Gonzalo Gonzalez ^c   Cano, Amparo ^b   Quintanilla, Miguel ^b   Ramon Y Cajal, Santiago ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b CSIC   (Spain)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Adenovirus E1A gene; Adenovirus E1B; E1B defective adenovirus; Gene therapy; Tumorigenicity

Indexed keywords

E1B PROTEIN;

ADENOVIRUS; ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CERCOPITHECUS; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; VERO CELL; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMALS; APOPTOSIS; CERCOPITHECUS AETHIOPS; HUMANS; NEOPLASMS; TUMOR CELLS, CULTURED; VERO CELLS; VIRUS REPLICATION;

EID: 0033219612     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700077     Document Type: Article

References (58)

1. Bishop JM. Molecular themes in oncogenesis. Cell. 1991; 64:235-248.
2. Ramon y Cajal S, Suster S, Halaban R, Filvaroff E, Dotto GP. Induction of different morphological patterns of malignant melanoma in mice after transformation with bFGF, H-ras, myc, neu, and Ela oncogenes. Am J Pathol. 1991; 138:349-358.
3. Woodruff MFA. Cellular heterogeneity in tumors. Br J Cancer. 1983;47:589-594.
4. Freeman SM, Whartenby KA, Freeman JL, et al. In situ use of suicide genes for cancer therapy. Semin Oncol. 1996;23:31-45.
5. Hinds PW, Weinberg RA. Tumor suppressor genes. Curr Opin Genet Dev. 1994;4:135-141.
6. Hunter T. Oncoprotein networks. Cell. 1997;88:333-346.
7. Kinzler KW, Vogelstein V. Gatekeepers and caretakers. Nature. 1997;386:761-763.
8. Desmaze C, Brizard F, Turc-Carel C, et al. Multiple chromosomal mechanisms generate an EWS/FLI1 or an EWS/ERG fusion gene in Ewing tumors. Cancer Genet Cytogenet. 1997;97:12-19.
9. Rabbits TH. The clinical significance of fusion oncogenes in cancer. N Engl J Med. 1998;338:192-194.
10. Anderson WF. Human gene therapy. Science. 1992;256: 808-813.
11. Barinaga M. Designing therapies that target tumor blood vessels. Science. 1997;275:482-484.
12. Blau HM, Springer ML. Gene therapy: a novel form of drug delivery. N Engl J Med. 1995;333:1204-1207.
13. Cournoyer D, Caskey CT. Gene therapy of the immune system. Annu Rev Immunol. 1993;11:297-329.
14. Carbone DP, Minna JD. In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirus. J Natl Cancer Inst. 1994;86:143-144.
15. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994;54:2287-2291.
16. Huang HJS, Yee JK, Shew JY, et al. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science. 1988;242:1563-1566.
17. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
18. Liu TJ, Zhang WW, Taylor DL, et al. Growth suppression of human head and neck cells by introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 1994;54:3662-3667.
19. Molten FL. Drug sensitivity (suicide) genes for selective cancer chemotherapy. Cancer Gene Ther. 1994;1:279-287.
20. Sánchez-Prieto R, Quintanilla M, Cano A, et al. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene. 1996;13:1083-1092.
21. Bayley ST, Mymryk JS. Adenovirus E1A proteins and transformation. Int. J Oncol. 1994;5:425-444.
22. Dyson N, Harlow E. Adenovirus E1A targets key regulators of cell proliferation. Cancer Surv. 1992;12:161-195.
23. Mymryk JS. Tumor suppressive properties of the adenovirus 5 E1A oncogene. Oncogene. 1996;13:1581-1589.
24. Datto MB, Hu PP, Kowalik TF, Yingling J, Wang XF. The viral oncoprotein E1A blocks transforming growth factor β-mediated induction of p21/WAF1/Cip1 and p15/INK4B. Mol Cell Biol. 1997;17:2030-2037.
25. Frisch SM, Francis H. Disruption of epithelial cell matrix interactions induces apoptosis. J Cell Biol. 1994;124:619-626.
26. Liu F, Green MR. Promoter targeting by adenovirus E1A through interaction with different cellular DNA-binding domains. Nature. 1994;368:520-525.
27. Kip1 by the viral E1A oncoprotein in TGFβ-treated cells. Nature. 1996;380:262-265.
28. Somasundaram K, El-Deiry WS. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene. 1997;14:1047-1057.
29. Evan G. Cancer, a matter of life and cell death. Int J Cancer. 1997;71:709-711.
30. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature. 1996;382:511-517.
31. Qin XQ, Livingston DM, Kaelin WG, Adams PD. Deregulated transcription factor E2F-1 expression leads S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA. 1994;91:10918-10922.
32. Frisch SM. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc Natl Acad Sci USA. 1991;88:9077-9081.
33. Sánchez-Prieto R, Quintanilla M, Martín P, et al. In vivo tumor suppressor effect of retrovirus gene transfer of the adenovirus E1a gene. Cancer Gene Ther. 1998;5:215-224.
34. Zhang Y, Yu D, Xia W, Hung MC. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene. 1995;10:1947-1954.
35. Chang JY, Xia W, Shao R, et al. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene. 1997;14:561-568.
36. Frisch SM. The epithelial cell default-phenotype hypothesis and its implications for cancer. Bioassays. 1997;19:705-709.
37. Frisch SM, Reich R, Collier IE, Genrich T, Martin G, Goldberg GI. Adenovirus E1A represses protease gene expression and inhibits metastasis of human cells. Oncogene. 1997;5:75-83.
38. Marcehetti E, Romero J, Sanchez R, Vargas JA, Lacal JC, Ramon y Cajal S. Oncogenes and cellular sensitivity to radiotherapy: a study on murine keratinocytes transformed by v-H-ras, v-myc, neu, adenovirus E1a, and p53 mutant. Int J Oncol. 1994;5:611-618.
39. Sanchez R, Lleonart M, Ramon y Cajal S. Lack of correlation between p53 protein level and sensitivity to DNA-damaging agents in keratinocytes carrying adenovirus E1A mutants. Oncogene. 1995;11:675-682.
40. Sanchez-Prieto R, Vargas JA, Carnero A, et al. Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes. Int J Cancer. 1995;60:235-243.
41. Marcellus RC, Teodoro JG, Wu T, et al. Adenovirus type 5 early region 4 is responsible for E1A-induced p53-independent apoptosis. J Virol. 1996;70:6207-6215.
42. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
43. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumorspecific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3:639-645.
44. Martin P, Alonso C, Sanchez-Prieto R, Quintanilla M, Ramon y Cajal S. Antitumoral effect of E1B-defective adenoviruses in human malignant cells. Gene Ther. 1998; 5:286-287.
45. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early IB protein. Nature. 1992;357:82-85.
46. Babiss LE, Fisher PB, Ginsberg HS. Effect on transformation of mutations in the early region lb-encoded 21 and 55-kilodalton proteins of adenovirus 5. J Virol. 1984;52: 389-395.
47. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59-72.
48. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ, ed. Methods in Molecular Biology: Gene transfer and Expression Protocols. Clifton, New Jersey: The Human Press; 1991:109-128.
49. Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. Anal Biochem. 1986;159: 109-113.
50. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985; 150:76-85.
51. Teodoro JG, Shore GC, Branton PE. Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms. Oncogene. 1995;11:467-474.
52. Teodoro JG, Branton PE. Regulation of p53-dependent apoptosis, transcriptional repression, and cell transformation by phosphorylation of the 55-kilodalton E1B protein of human adenovirus type 5. J Virol. 1997;71:3620-3627.
53. White E, Cipriani R, Sabattini P, Danton A. Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. J Virol. 1991;65:2968-2978.
54. Chiou S, White E. p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. J Virol. 1997;71:3515-3525.
55. Subramanian T, Tarodi B, Chinnadurai G. p53-independent apoptotic and necrotic cell deaths induced by adenovirus infection: suppression by E1B 19K and Bcl-2 proteins. Cell Growth Differ. 1995;6:131-137.
56. Schwartz LM, Smith SW, Jones MEE, Osborne BA. Do all programmed cell deaths occur via apoptosis? Proc Natl Acad Sci USA. 1993;90:980-984.
57. Hirsch T, Marchetti P, Susin Santos A, et al. The apoptosis-necrosis paradox: apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene. 1997;15:1573-1581.
58. Mymryk JS, Shire K, Bayley ST. Induction of apoptosis by adenovirus type 5 E1A in rat cells requires a proliferation block. Oncogene. 1994;9:1187-1193.